Your browser doesn't support javascript.
loading
Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets.
Petkeviciene, Janina; Voeller, Alexis; Ciupkeviciene, Egle; Razavi-Shearer, Devin; Liakina, Valentina; Jancoriene, Ligita; Kazenaite, Edita; Zaksas, Viaceslavas; Urbonas, Gediminas; Kupcinskas, Limas.
Afiliação
  • Petkeviciene J; Health Research Institute, Faculty of Public Health, Lithuanian University of Health Sciences, Tilzes str. 18, LT47181, Kaunas, Lithuania. janina.petkeviciene@lsmu.lt.
  • Voeller A; Department of Preventive Medicine, Faculty of Public Health, Lithuanian University of Health Sciences, Tilzes str. 18, LT47181, Kaunas, Lithuania. janina.petkeviciene@lsmu.lt.
  • Ciupkeviciene E; Center for Disease Analysis Foundation, 1120 W South Boulder Rd, Suite 102, Lafayette, CO, USA.
  • Razavi-Shearer D; Health Research Institute, Faculty of Public Health, Lithuanian University of Health Sciences, Tilzes str. 18, LT47181, Kaunas, Lithuania.
  • Liakina V; Center for Disease Analysis Foundation, 1120 W South Boulder Rd, Suite 102, Lafayette, CO, USA.
  • Jancoriene L; Faculty of Medicine, Vilnius University, Universiteto str. 3, LT01513, Vilnius, Lithuania.
  • Kazenaite E; Faculty of Fundamental Sciences, Vilnius Tech, Sauletekio av. 11, LT10223, Vilnius, Lithuania.
  • Zaksas V; Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University, Santariskiu str. 14, 08406, Vilnius, Lithuania.
  • Urbonas G; Faculty of Medicine, Vilnius University, Universiteto str. 3, LT01513, Vilnius, Lithuania.
  • Kupcinskas L; Vilnius University Hospital Santaros Klinikos, Santariskiu str. 2, LT08661, Vilnius, Lithuania.
BMC Public Health ; 24(1): 1055, 2024 Apr 15.
Article em En | MEDLINE | ID: mdl-38622549
ABSTRACT

BACKGROUND:

The World Health Organization (WHO) has outlined a set of targets to achieve eliminating hepatitis C by 2030. In May 2022, Lithuanian health authorities initiated a hepatitis C virus (HCV) screening program to start working towards elimination. In the program, bonus was given to general practitioners (GPs) to promote and conduct anti-HCV tests for two situations (1) one time testing for individuals born in 1945-1994 and (2) annual HCV testing for persons who inject drugs or are living with human immunodeficiency virus (HIV) regardless of age. This study aimed to model the current viral hepatitis C epidemiological status in Lithuania and to outline the requirements for WHO elimination targets using the first-year HCV screening results.

METHODS:

Individuals were invited to participate in the anti-HCV screening by GPs during routine visits. Patients who tested positive were then referred to a gastroenterologist or infectious disease doctor for further confirmatory testing. If a patient received a positive RNA test and a fibrosis staging result of ≥ F2, the doctor prescribed direct-acting antivirals. Information on the patients screened, diagnosed, and treated was obtained from the National Health Insurance Fund. The Markov disease progression model, developed by the CDA Foundation, was used to evaluate the screening program results and HCV elimination progress in Lithuania.

RESULTS:

Between May 2022 and April 2023, 790,070 individuals underwent anti-HCV testing, with 11,943 individuals (1.5%) receiving positive results. Anti-HCV seroprevalence was found to be higher among males than females, 1.9% and 1.2%, respectively. Within the risk population tested, 2087 (31.1%) seropositive individuals were identified. When comparing the screening program results to WHO elimination targets through modelling, 2180 patients still need to be treated annually until 2030, along with expanding fibrosis restrictions. If an elimination approach was implemented, 1000 new infections would be prevented, while saving 150 lives and averting 90 decompensated cirrhosis cases and 110 hepatocellular carcinoma cases.

CONCLUSIONS:

During the first year of the Lithuanian screening program, GPs were able to screen 44% of the target population. However, the country will not meet elimination targets as it currently stands without increasing treatment levels and lifting fibrosis restrictions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Abuso de Substâncias por Via Intravenosa / Hepatite C / Hepatite C Crônica / Usuários de Drogas Limite: Aged / Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Abuso de Substâncias por Via Intravenosa / Hepatite C / Hepatite C Crônica / Usuários de Drogas Limite: Aged / Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article